A detailed history of Tower Research Capital LLC (Trc) transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 23,233 shares of IOVA stock, worth $198,642. This represents 0.01% of its overall portfolio holdings.

Number of Shares
23,233
Previous 33,699 31.06%
Holding current value
$198,642
Previous $270,000 19.26%
% of portfolio
0.01%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.28 - $11.9 $76,192 - $124,545
-10,466 Reduced 31.06%
23,233 $218,000
Q2 2024

Aug 13, 2024

BUY
$7.78 - $14.19 $60,302 - $109,986
7,751 Added 29.87%
33,699 $270,000
Q1 2024

May 15, 2024

BUY
$7.59 - $17.47 $94,647 - $217,850
12,470 Added 92.52%
25,948 $384,000
Q4 2023

Feb 13, 2024

BUY
$3.3 - $8.89 $640 - $1,724
194 Added 1.46%
13,478 $109,000
Q3 2023

Nov 14, 2023

BUY
$4.44 - $8.79 $6,868 - $13,598
1,547 Added 13.18%
13,284 $60,000
Q2 2023

Aug 14, 2023

SELL
$5.36 - $9.06 $4,357 - $7,365
-813 Reduced 6.48%
11,737 $82,000
Q1 2023

May 09, 2023

SELL
$5.53 - $8.22 $105,009 - $156,089
-18,989 Reduced 60.21%
12,550 $76,000
Q4 2022

Feb 10, 2023

SELL
$5.62 - $10.0 $138,971 - $247,280
-24,728 Reduced 43.95%
31,539 $201,000
Q3 2022

Nov 10, 2022

BUY
$9.53 - $13.11 $293,361 - $403,565
30,783 Added 120.79%
56,267 $539,000
Q2 2022

Aug 15, 2022

BUY
$6.38 - $18.33 $144,264 - $414,477
22,612 Added 787.33%
25,484 $281,000
Q1 2022

May 12, 2022

BUY
$12.38 - $19.1 $31,197 - $48,132
2,520 Added 715.91%
2,872 $48,000
Q4 2021

Feb 14, 2022

SELL
$16.55 - $27.63 $4,998 - $8,344
-302 Reduced 46.18%
352 $6,000
Q3 2021

Nov 15, 2021

SELL
$20.35 - $26.63 $58,302 - $76,294
-2,865 Reduced 81.42%
654 $17,000
Q2 2021

Aug 16, 2021

SELL
$16.33 - $33.07 $1.37 Million - $2.77 Million
-83,836 Reduced 95.97%
3,519 $92,000
Q1 2021

May 17, 2021

BUY
$28.67 - $52.59 $1.49 Million - $2.73 Million
51,975 Added 146.91%
87,355 $2.77 Million
Q4 2020

Feb 16, 2021

BUY
$28.04 - $50.26 $889,008 - $1.59 Million
31,705 Added 862.72%
35,380 $1.64 Million
Q3 2020

Nov 16, 2020

SELL
$27.75 - $36.3 $530,108 - $693,438
-19,103 Reduced 83.87%
3,675 $121,000
Q2 2020

Aug 13, 2020

BUY
$27.21 - $41.0 $619,789 - $933,898
22,778 New
22,778 $625,000
Q1 2020

May 15, 2020

SELL
$19.54 - $38.85 $5,490 - $10,916
-281 Closed
0 $0
Q4 2019

Feb 07, 2020

SELL
$17.95 - $29.41 $105,474 - $172,813
-5,876 Reduced 95.44%
281 $8,000
Q3 2019

Nov 05, 2019

BUY
$17.99 - $26.0 $89,176 - $128,882
4,957 Added 413.08%
6,157 $112,000
Q2 2019

Aug 13, 2019

BUY
$9.78 - $24.52 $11,736 - $29,424
1,200 New
1,200 $29,000
Q4 2018

Feb 14, 2019

SELL
$7.51 - $11.93 $66,403 - $105,485
-8,842 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$11.25 - $17.7 $85,758 - $134,927
7,623 Added 625.35%
8,842 $99,000
Q2 2018

Aug 15, 2018

BUY
$12.45 - $16.95 $14,504 - $19,746
1,165 Added 2157.41%
1,219 $16,000
Q1 2018

May 15, 2018

SELL
$8.1 - $19.5 $5,005 - $12,051
-618 Reduced 91.96%
54 $1,000
Q4 2017

Feb 09, 2018

SELL
$6.65 - $9.25 $56,644 - $78,791
-8,518 Reduced 92.69%
672 $5,000
Q3 2017

Nov 14, 2017

BUY
$4.45 - $8.55 $40,895 - $78,574
9,190
9,190 $71,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.35B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.